BrainStorm Cell Therapeutics Receives Patents for Allogeneic Exosome Platform-Product, Revolutionizing Neurological Disorder Treatments
NEW YORK, Dec. 26, 2023 - BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a pioneering developer of adult stem cell therapeutics targeted at neurodegenerative diseases, announced today the exciting news of the successful grant and allowance of three patent applications for its groundbreaking NurOwn and NurOwn-Exosomes technologies. These patents mark a significant milestone in the field of neurology, showcasing BrainStorm’s commitment to transforming the landscape of neurological disorder treatments.
BrainStorm’s innovative approach revolves around harnessing the power of exosomes, tiny cell-derived vesicles that act as potent intercellular messengers, capable of transferring genetic material and signaling molecules between cells. By isolating these exosomes derived from adult stem cells, BrainStorm has unlocked a potentially game-changing solution for treating neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and Alzheimer’s disease among others.
The granted patents validate BrainStorm’s intellectual property rights and protect the company’s novel exosome technology platform. These patents cover the methods of generating and propagating exosome-based therapies, ensuring BrainStorm’s exclusive rights to develop and commercialize products targeting neurological disorders.
NurOwn, BrainStorm’s lead technology, has already showcased its therapeutic potential in multiple clinical trials. It utilizes autologous (self-derived) mesenchymal stem cells, which are first harvested from the patient’s bone marrow before being expanded and differentiated into specialized cells known asurinduced cells (NICs). These NICs are then induced to produce therapeutically beneficial factors, including neurotrophic factors, before being encapsulated in the exosomes for delivery.
The proprietary NurOwn-Exosomes platform builds upon the success of NurOwn, offering an allogeneic (donor-derived) approach whereby the stem cells are sourced from healthy donors rather than the patients themselves. This streamlined process provides a readily available and scalable therapeutic solution that eliminates the need for individualized stem cell derivation, reducing costs and complexity associated with patient-specific treatments.
BrainStorm’s patented exosome-based technology offers numerous advantages over other traditional treatment modalities and has the potential to revolutionize neurodegenerative disease management. The encapsulation of therapeutic factors within exosomes ensures their efficient delivery and protection from degradation, facilitating targeted and sustained release to the affected cells. This localized treatment approach minimizes potential off-target effects and maximizes the therapeutic benefits while limiting systemic exposure.
With the grant of these patents, BrainStorm is at the forefront of a promising new era in neurology. The company’s commitment to research and development, coupled with its innovative exosome platform, ushers in a new paradigm for treating neurological disorders. BrainStorm’s advancements hold the potential to significantly improve the lives of countless patients, offering hope for better outcomes and potentially even disease modification.
In a field that was previously fraught with challenges, the emergence of BrainStorm’s allogeneic exosome platform-product transforms the way we approach and address neurological disorders. With this crucial breakthrough, BrainStorm paves the way for more targeted, effective, and accessible treatment options, underscoring their standing as a leader in neurodegenerative disease therapeutics.
Comments